Use of High Resolution Colonic Manometry in Studying Motility

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-13

Study Completion Date

2018-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An injury to the spinal cord (SCI) results in numerous medical complications, including gastrointestinal (GI) function. Individuals with SCI may experience severe constipation (prolonged stool retention), incontinence (accidents), and overall difficulty in bowel evacuation. While various treatments and medications have been established to address this complication, there is little knowledge relating to the overall colonic motility. However, new technology such as High Resolution Colonic Manometry allows physicians to visualize high pressure contractions inside the colon, leading to a greater understanding of typical motility, a more accurate diagnosis, and an effective treatment. In this study, the investigators propose to use this technology to understand the effects of SCI on colonic motility by comparing to normal colonic function observed in able-bodied (AB) individuals. In addition, the investigators plan to study the effects of pharmacological treatments, such as neostigmine, on promoting peristaltic contractions in the colon as it is delivered across the skin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation

NCT02784093

Fecal Impaction

UNKNOWN PHASE2

Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

NCT01781104

Constipation

COMPLETED PHASE2

Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?

NCT00949377

Colonic Inertia

WITHDRAWN PHASE4

Use of Pyridostigmine for Constipation in Diabetics

NCT00276406

Constipation Diabetes Mellitus Colonic Transit +1 more

COMPLETED PHASE1/PHASE2

Defecation Patterns in Constipated Patients

NCT04903470

Constipation by Outlet Obstruction

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators data suggests that the fundamental consequence of SCI is a slowing of intestinal peristaltic activity, most likely as a result of down regulation of parasympathetic neural pathways. Furthermore, the investigators have effectively shown that measures involved in increase parasympathetic stimulation results in efficient bowel evacuation and improved bowel care. Such measures include the administration of neostigmine (NEO), which increases peristaltic contractions in the colon, resulting in predictable bowel evacuations. Given the cardiopulmonary side-effects of NEO, an ant-cholinergic known as Glycopyrrolate (GLY) is usually co-administered with NEO to reverse these side effects. However, the investigators knowledge regarding the effects of SCI on colonic motility is still primitive, mainly due to pervious technological disadvantages. New High Resolution Colonic Manometry systems (Medical Measurement Systems Dover, NH) simultaneously capture high amplitude pressure contractions (HAPCs) across the ascending, transverse, descending, and recto-sigmoid colon. Such capabilities allow for a much clearer display of pressure events compared to previous line tracing manometric systems and the direction of contractions are much easier to discern as well. To date, this technology has been an effective tool in diagnosing bowel disorders and complications, such as constipation in able-bodied individuals (AB). However, such studies have not been conducted in a SCI population. This technology also has the potential to capture the effects of NEO+GLY on improving colonic function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrointestinal Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SCI observational

Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a "typical" day (eating, sleeping, mobility, etc.).

Group Type EXPERIMENTAL

High Resolution Colonic Manometry

Intervention Type DEVICE

Able-bodied observational

Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a "typical" day (eating, sleeping, mobility, etc.).

Group Type EXPERIMENTAL

High Resolution Colonic Manometry

Intervention Type DEVICE

SCI drug group

Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.

Group Type ACTIVE_COMPARATOR

Neostigmine

Intervention Type DRUG

Glycopyrrolate

Intervention Type DRUG

High Resolution Colonic Manometry

Intervention Type DEVICE

SCI placebo group

Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).

Group Type PLACEBO_COMPARATOR

Saline (Placebo)

Intervention Type OTHER

High Resolution Colonic Manometry

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neostigmine

Intervention Type DRUG

Glycopyrrolate

Intervention Type DRUG

Saline (Placebo)

Intervention Type OTHER

High Resolution Colonic Manometry

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic SCI \>1year
* Able-Bodied (non SCI)
* Undergoing Elective Colonoscopy
* Age 18-75 years.

Exclusion Criteria

* Previous adverse reaction or hypersensitivity to electrical stimulation
* Known sensitivity to neostigmine or glycopyrrolate
* Persons with SCI who do not require additional bowel care or have "normal bowel function"
* Known hypersensitivity to neostigmine or glycopyrrolate
* History of mechanical obstruction of the intestine or urinary tract
* History of Myocardial infarction
* Uncontrollable Hypertension Defined by a blood pressure reading of 160/100 mmHg or higher
* Organ damage (heart \& kidney) and/or transient ischemic attack-cerebral vascular accident as a result of hypertension
* Known past history of coronary artery disease or bradyarrythmia
* Active respiratory disease
* Known history of asthma during lifetime or recent (within 3 months) respiratory infections
* Adrenal insufficiency
* Diagnosed coagulopathy
* Any renal disease or dysfunction
* Potential for pregnancy
* Lactating/nursing females
* Slow-heart beat (HR\<45 bpm)
* Lack of mental capacity to give consent
* Use of any antibiotic in the past 7 days
* Use of medications known to affect the respiratory system
* Use of medications known to alter airway caliber
* Concurrent participation in other clinical trials (within 30 days)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes